252 related articles for article (PubMed ID: 7583074)
1. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).
Dahlman T; Hartvig P; Löfholm M; Nordlinder H; Lööf L; Westermark K
QJM; 1995 Sep; 88(9):609-16. PubMed ID: 7583074
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.
Haslam RH; Sass-Kortsak A; Stout W; Berg M
Dev Pharmacol Ther; 1980; 1(5):318-24. PubMed ID: 7438976
[TBL] [Abstract][Full Text] [Related]
4. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease.
Schumacher G; Platz KP; Mueller AR; Neuhaus R; Steinmüller T; Bechstein WO; Becker M; Luck W; Schuelke M; Neuhaus P
Clin Transplant; 1997 Jun; 11(3):217-24. PubMed ID: 9193846
[TBL] [Abstract][Full Text] [Related]
5. Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine.
Lowette KF; Desmet K; Witters P; Laleman W; Verslype C; Nevens F; Fevery J; Cassiman DM
Eur J Gastroenterol Hepatol; 2010 May; 22(5):564-71. PubMed ID: 20042865
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc.
Askari FK; Greenson J; Dick RD; Johnson VD; Brewer GJ
J Lab Clin Med; 2003 Dec; 142(6):385-90. PubMed ID: 14713890
[TBL] [Abstract][Full Text] [Related]
7. Wilson disease in children: serum aminotransferases and urinary copper on triethylene tetramine dihydrochloride (trientine) treatment.
Arnon R; Calderon JF; Schilsky M; Emre S; Shneider BL
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):596-602. PubMed ID: 17460493
[TBL] [Abstract][Full Text] [Related]
8. Histologic evolution and long-term outcome of Wilson's disease: results of a single-center experience.
Sini M; Sorbello O; Sanna F; Battolu F; Civolani A; Fanni D; Faa G; Demelia L
Eur J Gastroenterol Hepatol; 2013 Jan; 25(1):111-7. PubMed ID: 23011036
[TBL] [Abstract][Full Text] [Related]
9. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease.
Scheinberg IH; Jaffe ME; Sternlieb I
N Engl J Med; 1987 Jul; 317(4):209-13. PubMed ID: 3600712
[TBL] [Abstract][Full Text] [Related]
10. Neurological abnormalities in Wilson's disease are reversible.
Lingam S; Wilson J; Nazer H; Mowat AP
Neuropediatrics; 1987 Feb; 18(1):11-2. PubMed ID: 3561699
[TBL] [Abstract][Full Text] [Related]
11. Wilson's disease presenting with features of hepatic dysfunction: a clinical analysis of eighty-seven patients.
Walshe JM
Q J Med; 1989 Mar; 70(263):253-63. PubMed ID: 2602537
[TBL] [Abstract][Full Text] [Related]
12. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
[TBL] [Abstract][Full Text] [Related]
14. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
15. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
Walshe JM
Q J Med; 1973 Jul; 42(167):441-52. PubMed ID: 4728043
[No Abstract] [Full Text] [Related]
16. Wilson's disease with depression and parkinsonism.
Chan KH; Cheung RT; Au-Yeung KM; Mak W; Cheng TS; Ho SL
J Clin Neurosci; 2005 Apr; 12(3):303-5. PubMed ID: 15851088
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
[TBL] [Abstract][Full Text] [Related]
18. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and management of Wilson's disease: results of a single center experience.
Medici V; Trevisan CP; D'Incà R; Barollo M; Zancan L; Fagiuoli S; Martines D; Irato P; Sturniolo GC
J Clin Gastroenterol; 2006; 40(10):936-41. PubMed ID: 17063115
[TBL] [Abstract][Full Text] [Related]
20. Trientine-induced neurological deterioration in a patient with Wilson's disease.
Kim B; Chung SJ; Shin HW
J Clin Neurosci; 2013 Apr; 20(4):606-8. PubMed ID: 23274038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
